Ads
related to: keytruda cancer drug- ENHERTU® Information
Learn More About ENHERTU® and How
it is Thought to Work.
- ENHERTU® Safety Info
Important Side Effect Information
for Patients and Caregivers.
- ENHERTU® Data
Access Important Data on How
ENHERTU® Performed in Studies.
- ENHERTU® Resources
Access Free Patient Resources Like
a Downloadable Brochure.
- ENHERTU® Information
Search results
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga via Yahoo Finance· 6 days agoKeytruda (pembrolizumab) is Merck & Co Inc’s (NYSE:MRK) top selling cancer drug. The abstract...
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence - Merck & Co...
Benzinga· 2 days agoMerck & Co., Inc. MRK is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum...
TILT Biotherapeutics reports data from Phase I trial of ovarian cancer treatment
Clinical Trials Arena via Yahoo Finance· 3 days agoTILT-123 is an oncolytic adenovirus featuring tumour necrosis factor alpha (TNFα) and interleukin-2...
Tumors shrink for 62% of patients in Merck study
Becker’s Hospital Review· 2 days agoIn a phase 2/3 trial investigating the efficacy of Keytruda with two chemotherapies, tumors shrank among 3 in 5 patients with pleural mesothelioma, Merck said May 29. It often ...
Merck to pay as much as $3 billion for eye treatment startup
Crain's New York Business· 1 day agoWhile it raised its profit and sales forecast for the year on Keytruda sales, Merck has been on the...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Reuters via Yahoo Finance· 2 days agoMerck has said it's in the market for deals of up to around $15 billion as it plans ways to deal...
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
Barrons.com· 6 days agoThe American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual...
Merck to acquire eye drug company EyeBio for up to $3 billion
WSAU Wausau· 2 days ago(Reuters) - Merck said on Wednesday it would acquire eye diseasedrug developer EyeBio for up to $3...
Why This Top 4% Biotech Just Catapulted To A Record High
Investor's Business Daily· 6 days agoThe Netherlands-based biotech paired its drug, petosemtamab, with Merck's (MRK) cancer blockbuster, ...
Roche’s Sabry retires; Duchenne drug fails confirmatory test
BioPharma Dive via Yahoo Finance· 3 days agoThe veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative...
Ads
related to: keytruda cancer drug